External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model
Key result
The COMPASS-CAT risk assessment model showed moderate discrimination (AUC 0.62) for predicting VTE at 6 months, with VTE rates of 6.31% in high-risk vs 2.27% in low/intermediate-risk groups.
Why the study?
Current VTE risk assessment models show poor predictive value in common cancers, so the authors sought to externally validate the COMPASS-CAT model in outpatient cancer patients.
Does the COMPASS-CAT risk assessment model accurately predict venous thromboembolism in outpatients with solid tumors?
Population
3,814 patients aged ≥18 years with invasive breast, ovarian, lung, or colorectal cancers
Comparison
Low/intermediate-risk vs high-risk groups stratified by the COMPASS-CAT RAM
Design
Retrospective external validation study
Follow-up
6-month follow-up
Authors
Discussion
Loading...
Member takes
Implication
COMPASS-CAT shows moderate VTE discrimination in cancer outpatients; leaves open clinical adoption pending prospective validation.
Study Design
Type
Observational (n=3,814)
Multicenter
No
Structured PICO
Does the COMPASS-CAT risk assessment model accurately predict venous thromboembolism in outpatients with solid tumors?
P
Population
3,814 patients aged ≥18 years with invasive breast, ovarian, lung, or colorectal cancers, followed for 6 months.
E
Exposure
COMPASS-CAT Venous Thromboembolism Risk Assessment Model
O
Outcome
Documented VTE at 6-month follow-uphard clinical
Main Result
Absolute Event Rate: 6.31% vs 2.27%
The COMPASS-CAT risk model showed moderate discrimination and poor calibration but good negative predictive value for VTE in cancer outpatients, suggesting further prospective validation is needed.
Limitations
- Retrospective design
- Moderate model discrimination and poor calibration
Cite This Study
Spyropoulos et al. (2020) conducted an observational in Invasive breast, ovarian, lung, or colorectal cancer (n=3,814). COMPASS-CAT RAM high-risk stratification vs. Low/intermediate-risk stratification was evaluated on Documented VTE at 6-month follow-up. The COMPASS-CAT risk assessment model showed moderate discrimination (AUC 0.62) for predicting VTE at 6 months, with VTE rates of 6.31% in high-risk vs 2.27% in low/intermediate-risk groups.